Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Akira Okita 1, 2 , Shin Takahashi 1, 2 , Kota Ouchi 1, 2 , Masahiro Inoue 3 , Mika Watanabe 4 , Mareyuki Endo 5 , Hiroshi Honda 6 , Yasuhide Yamada 7, 8 and Chikashi Ishioka 1, 2 1 Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Japan 2 Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Japan 3 Department of Clinical Oncology, Akita University Graduate School of Medicine, Akita, Japan 4 Department of Pathology, Tohoku University Graduate School of Medicine, Aobaku, Sendai, Japan 5 Department of Pathology, Sendai Kousei Hospital, Aobaku, Sendai, Japan 6 Department of Surgery, Tohoku Rosai Hospital, Aobaku, Sendai, Japan 7 Department of Clinical Oncology, Hamamatsu University School of Medicine, Higashiku, Hamamatsu, Japan 8 Department of Oncology, National Center for Global Health and Medicine, Tokyo, Japan Correspondence to: Chikashi Ishioka, email: chikashi@tohoku.ac.jp Keywords: consensus molecular subtypes; chemotherapeutic efficacy; predictive biomarkers; colorectal cancer; DNA methylation status Received: October 26, 2017 Accepted: February 24, 2018 Published: April 10, 2018 ABSTRACT The consensus molecular subtypes (CMS) classification is one of the most robust colorectal cancer (CRC) classifications based on comprehensive gene expression profiles. This study aimed to clarify whether the CMS is a predictive factor for therapeutic effects of standard chemotherapies for metastatic CRC (mCRC). We retrospectively enrolled 193 patients with mCRCs, and using comprehensive gene expression data, classified them into 4 subtypes: CMS1–CMS4. The associations between the subtypes and treatment outcomes were analyzed. Regarding first-line chemotherapy, irinotecan (IRI)-based chemotherapy was significantly superior to oxaliplatin (OX)-based chemotherapy for progression-free survival (PFS; hazard ratio [HR] = 0.31, 95% confidence interval [CI] 0.13–0.64) and overall survival (OS; HR = 0.45, 95% CI 0.19–0.99) in CMS4. Regarding the anti-epidermal growth factor receptor (anti-EGFR) therapy, CMS1 showed particularly worse PFS (HR = 2.50, 95% CI 1.31–4.39) and OS (HR = 4.23, 95% CI 1.83–9.04), and CMS2 showed particularly good PFS (HR = 0.67, 95% CI 0.44–1.01) and OS (HR = 0.49, 95% CI 0.27–0.87) compared with the other subtypes. The biological characteristics of CMS may influence the efficacy of chemotherapy. CMS might be a new predictive factor for the efficacy of chemotherapy against mCRCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 5×
“The molecular biological characteristics of each subtype were similar to those previously reported (Supplementary Table 6), and the prognosis in this study (OS) also showed a trend similar to that in the previous study (survival after relapse) [22].”
InfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“Chemotherapy options for mCRC are diverse, and several treatment regimens use cytotoxic agents and molecular-targeted agents either alone or in combination with other drugs www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 27), pp: 18698-18711 Research Paper www.oncotarget.com [5].”
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“RAS mutation is a biomarker for predicting resistance to anti-epidermal growth factor receptor (anti-EGFR) antibodies, and its status is essential for determining the therapeutic indication of anti-EGFR antibodies [6–9].”
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 1×
“The median survival time of metastatic colorectal cancer (mCRC) has been reported to be approximately 8 months with palliative treatment [2], which extends to 25.8–31.4 months when standard chemotherapy is administered [3, 4].”
InfluentialDe Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771 · cited 1×
“This is also consistent with the previous reports [19, 36, 37, 40].”
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
Colorectal Cancer Collaborative Group (2000) · BMJ · doi:10.1136/bmj.321.7260.531 · Cited by 662
Cited by
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
“Other supporting evidence for the benefit of anti-EGFR therapy compared with the addition of bevacizumab in CMS2 patients was shown with the IHC classifier (79), but also with NanoString-based classification (56), the CMS R package (69), and the CMScaller (76).”
BackgroundMethodInfluentialValdeolivas, A., Amberg, B., Giroud, N., Richardson, M., Gálvez, E. J. C., Badillo, S., Julien-Laferrière, A., Túrós, D., Voith von Voithenberg, L., Wells, I., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-023-00488-4 · Cited by 130
Investigation of colorectal cancer in accordance with consensus molecular subtype classification
Sawayama, H., Miyamoto, Y., Ogawa, K., Yoshida, N., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12362 · Cited by 60
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Genetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
Zhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2403 · Cited by 36
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
DNA Repair Capacity and Response to Treatment of Colon Cancer
Vodicka, P., Vodenkova, S., Buchler, T., & Vodickova, L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0070 · Cited by 19
Arai, H., Millstein, J., Loupakis, F., Stintzing, S., Wang, J., Battaglin, F., Kawanishi, N., Jayachandran, P., Soni, S., Zhang, W., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.048 · Cited by 2
Metadata
- Authors
- Okita, A., Takahashi, S., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-10
- Volume
- 9
- Issue
- 27
- Pages
- 18698-18711
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2796691218
- Cited by
- 155
- References
- 12
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.